Datopotamab Deruxtecan, often abbreviated as DATO, represents a important advancement within targeted cancer treatment. This new antibody-drug conjugate pairs a monoclonal antibody specifically directed at HER2 https://owainssck342904.blog-gold.com/57628854/dato-deruxtecan-a-encouraging-adc-link